AI in Life Sciences: Faster Cures for Viral Disease
COVID-19 is upending life as we know it. The potential effect of this viral disease on mortality and public health, as well as the lasting socioeconomic impact of the crisis, is unfathomable. To mitigate the wide-scale impact of this growing pandemic, our hopes are trained on a vaccine, prophylactic or curative, and the life sciences […]Read More
Value-Based Care in Life Sciences: What’s It Worth to You?
Just one of the many changes rippling through the life sciences industry is the gradual but inexorable shift of value-based care (VBC) becoming a leading means of healthcare insurance reimbursement. According to our recently sponsored research, as many as 150 biopharmaceutical drugs are covered by value-based contracts, with a projected growth rate of 15% to […]Read More
Disaggregation of Healthcare: The Great Unbundling Proceeds
In discussions with our clients, it’s become apparent that one of the greatest changes we’re witnessing in healthcare is the disaggregation (or unbundling) of care. Historically, access to and delivery of healthcare took place primarily in doctors’ offices, hospitals and clinics. However, changes in consumer sentiment and advances in technology are creating a far more […]Read More
From ‘-Omics’ to Digital Twins, Life Sciences Is In for Vast Changes Ahead
Digital tools and platforms are remaking every aspect of the life sciences (LS) value chain, from co-prescribed apps to implanted sensors to data queries for drug discovery, and digital is overturning how companies conduct clinical trials and manage production/distribution. The changes extend to how individual patients assimilate and internalize health and healthcare technology directly, through […]Read More